Recurrent Glioblastomas

Name: Recurrent Glioblastomas
Creator: NATIONAL INSTITUTES OF HEALTH
Published: 2026-03-31T00:00:00+00:00
Keywords: GRANT

NATIONAL INSTITUTES OF HEALTHHEALTH AND HUMAN SERVICES, DEPARTMENT OF.NATIONAL INSTITUTES OF HEALTH

AI Overview

Clinical trial evaluating LMP744 drug efficacy and safety in recurrent glioblastoma patients through molecular profiling and pharmacologic response assessment.

This summary is AI-generated from the official solicitation.

Key Details

Agency

NATIONAL INSTITUTES OF HEALTH

Funding Amount

—

Release Date

March 31, 2026

Due Date

April 15, 2026 (Closed)

Official Description

The goal of this clinical trial is to evaluate progression-free and overall survival in participants with recurrent glioblastoma receiving LMP744 compared to historic controls. We will also directly compare molecular and metabolic profiles of tissue, CSF, and plasma pre- and postexposure to LMP744 to determine pharmacologic responses to the drug in this patient population. We will also correlate the pre- and post-exposure molecular and metabolic profiles with clinical response and outcome, to de...

Read full description on official source

Get Alerts for Opportunities Like This

RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.

Start Free Trial